Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT07216443 is registered in ClinicalTrials.gov with Orca Biosystems, Inc. as lead sponsor.

NCT NCT07216443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07216443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Lead sponsor
Orca Biosystems, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
December 9, 2025
Completion date
December 31, 2028
Enrollment
80 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, acute, mixed phenotype acute leukemia, myelodysplastic syndromes